Cellesce is pleased to announce that it has successfully completed its organoid technology development project. Funded by InnovateUK (the UK’s innovation agency) and NC3Rs (leading the discovery and application of new technologies and approaches to replace, reduce and refine the use of animals for scientific purposes), the project ran from September 2014 to February 2016. Cellesce now has a process for the production of organoids at commercial grade and scale.

Organoids are a powerful new enabling technology in drug discovery and personalised medicine. An organoid is a miniature organ in a gel matrix, grown from stem cells and cultured with tailored growth factors. Because organoids are closer to tissue structure than other available tools, they give more accurate test results. However, up to now, growing organoids has been a labour-intensive manual process, subject to human error, volume constraints, and with significant process variability.

Cellesce has built and validated a scalable process for the expansion of organoids, free from these constraints – and is currently using this process to expand colorectal cancer organoids.

We are currently exploring opportunities to deploy this technology across a range of applications.